近期抗风湿药物对类风湿关节炎相关淋巴增殖性疾病特征的影响
在这项覆盖日本53家医院的多中心研究中,纳入752例类风湿关节炎相关淋巴增殖性疾病(RA-LPD)患者和770例散发性LPD患者,比较其临床病理特征。结果显示,发病前使用的抗风湿药物可能影响RA-LPD的临床病理特征,且LPD发病后仅使用托珠单抗(TCZ)的方案与自发消退后再生频率较低相关,推荐LPD发病后使用TCZ单药方案。
要点
- RA-LPD与散发性LPD的临床病理特征存在显著差异,RA-LPD中LPD相关免疫抑制状态频率高。
- 甲氨蝶呤(MTX)联合他克莫司组及MTX联合肿瘤坏死因子抑制剂(TNFi)组的受累部位频率和组织学亚型与单用MTX组不同。
- LPD发病后仅使用托珠单抗(TCZ)治疗与自发消退后再生频率较低相关,推荐LPD发病后使用TCZ单药方案。
核心结论
- 发病前使用的抗风湿药物可能影响RA-LPD的临床病理特征,且模式随时间变化。
- LPD发病后推荐使用托珠单抗(TCZ)单药方案。
研究设计与样本
- 多中心研究,覆盖日本53家医院,纳入1999年1月至2021年3月期间就诊的RA-LPD患者和散发性LPD患者。
- 统计方法包括Fisher精确检验、Mann-Whitney U检验、对数秩检验、逻辑回归分析和Cox比例风险模型。
主要发现
- 共纳入752例RA-LPD患者和770例散发性LPD患者。
- RA-LPD与散发性LPD的临床病理特征存在显著差异,组织病理学分析显示LPD相关免疫抑制状态频率高。
- MTX联合他克莫司组和MTX联合TNFi组的受累部位频率及组织学亚型与单用MTX组不同。
- MTX和TNFi可能协同影响对EB病毒感染的易感性。
- LPD发病后仅使用TCZ治疗与其他方案相比,自发消退后再生频率较低。
临床怎么用
- LPD发病后推荐使用托珠单抗(TCZ)单药方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study, we examine how advancements in novel antirheumatic drugs affect the clinicopathologic features of lymphoproliferative disorder (LPD) in patients with rheumatoid arthritis (RA). METHODS: In this multicenter study across 53 hospitals in Japan, we characterized patients with RA who developed LPDs and visited the hospitals between January 1999 and March 2021. The statistical tools used included Fisher's exact test, the Mann-Whitney U-test, the log-rank test, logistic regression analysis, and Cox proportional hazards models. RESULTS: Overall, 752 patients with RA-associated LPD (RA-LPD) and 770 with sporadic LPD were included in the study. We observed significant differences in the clinicopathologic features between patients with RA-LPD and those with sporadic LPD. Histopathological analysis revealed a high frequency of LPD-associated immunosuppressive conditions. Furthermore, patients with RA-LPD were evaluated based on the antirheumatic drugs administered. The methotrexate (MTX) plus tacrolimus and MTX plus tumor necrosis factor inhibitor (TNFi) groups had different affected site frequencies and histologic subtypes than the MTX-only group. Moreover, MTX and TNFi may synergistically affect susceptibility to Epstein-Barr virus infection. In case of antirheumatic drugs administered after LPD onset, tocilizumab (TCZ)-only therapy was associated with lower frequency of regrowth after spontaneous regression than other regimens. CONCLUSION: Antirheumatic drugs administered before LPD onset may influence the clinicopathologic features of RA-LPD, with patterns changing over time. Furthermore, TCZ-only regimens are recommended after LPD onset.
引用
- Hoshida Y, Tsujii A, Ohshima S, et al. Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis-Associated Lymphoproliferative Disorders. Arthritis Rheumatol. 2024. PMID: 38272827. doi:10.1002/art.42809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。